



AMP 2019 Board of Directors

President

Victoria M. Pratt, PhD

Indiana University Medical Center

Dr. Victoria Pratt is a Medical and Clinical Molecular Geneticist board-certified by the American College of Medical Genetics. She is the Director of the Pharmacogenomics Laboratory and Molecular Genetics Laboratory at Indiana University School of Medicine. Prior to joining Indiana University, she was Chief Director, Molecular Genetics, for Quest Diagnostics Nichols Institute.

Dr. Pratt is the President of Association for Molecular Pathology. Dr. Pratt is also the Past Chair of the Genetics, Clinical Practice and the Program committees and is currently a member of the Economic Affairs, Professional Relations committees for AMP. She is a former advisor of EurogenTest for genetic test validation. Dr. Pratt serves on the American Medical Association's (AMA) Molecular Pathology Current Procedural Terminology (CPT) Advisory committee.

In addition to her work, Dr. Pratt served on the Centers for Medicare and Medicaid Services Clinical Diagnostic Laboratory Tests Advisory Panel. Dr. Pratt continues to serve on the Centers for Disease Control and Prevention (CDC) GeT-RM program for reference materials for Molecular Genetics. She is currently serving on the National Academy of Medicine's (formerly Institute of Medicine) Roundtable on Genomics and Precision Health. She also served on the U.S. Secretary of Health and Human Services Advisory Committee on Genetics, Health and Society for the Oversight of Genetic Testing and the Advisory Committee on Hereditary Disorders in Newborns and Children. She also participated in the preparation of the Morbidity and Mortality Weekly Report for Best Practices in Molecular Genetic Testing for the CDC and the National Academy of Medicine's Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies.

Dr. Pratt has authored over 50 peer-reviewed manuscripts and book chapters. She is also an Associate Editor for the Journal of Molecular Diagnostics.

Dr. Pratt graduated with a Ph.D. in Medical and Molecular Genetics from Indiana University School of Medicine, Indianapolis, IN in 1994. Her fellowship training was in Ph.D. Medical and Clinical Molecular Genetics at Henry Ford Hospital, Detroit MI.

President-Elect

Karen Weck, MD

University of North Carolina

Dr. Karen Weck is Professor of Pathology & Laboratory Medicine and Professor of Genetics at the University of North Carolina in Chapel Hill, where she is Director of Molecular Genetics and Pharmacogenomics and Medical Director of the Clinical Molecular Genetic Pathology Laboratory.

Dr. Weck is the current President-Elect of the Association for Molecular Pathology and has served on multiple committees for AMP.

Dr. Weck received Bachelor of Science and Doctor of Medicine degrees from Duke University, residency training in Laboratory Medicine at Washington University in St. Louis, and is boarded in Clinical Pathology and Molecular Genetic Pathology. She has over 20 years' experience in developing molecular diagnostic testing.

Dr. Weck has been co-investigator of four NIH-funded grants to implement exome sequencing for diagnosis of genetic diseases from prenatal testing to adults and of the UNCseq tumor sequencing study to implement genomic sequencing for somatic mutation testing in cancer to identify response to specific pathway inhibitors. She has been co-investigator of several institutional clinical trials to study the clinical utility of pharmacogenomics guided therapy, including: CYP2D6 genotype-guided dosing for tamoxifen in breast cancer, CYP2C9/ VKORC1 genotype-guided dosing for warfarin, and CYP2C19 genotype-guided dosing for clopidogrel.

Dr. Weck has served as a consultant or advisor to numerous commercial and professional organizations and is a member of the FDA Molecular and Clinical Genetics Devices Panel. She is Past Chair of Molecular Pathology and Genomics Cluster, Biochemical and Molecular Genetics Resource Committee, and Pharmacogenomics Workgroup for the College of American Pathologists. She is an Associate Editor for the ACMG journal Genetics in Medicine and is a member of the editorial board for the Journal of Molecular Diagnostics.

Past President and Nominating Committee Chair

Kojo S. J. Elenitoba-Johnson, MD
University of Pennsylvania

Dr. Kojo S. J. Elenitoba-Johnson is the Peter C. Nowell, MD Professor at the Perelman School of Medicine at University of Pennsylvania and Founding Director of Penn Medicine's Center for Personalized Diagnostics. Dr. Elenitoba-Johnson is a Hematopathologist and Molecular Pathologist and leverages high dimensional approaches, such as integrative genomics and mass spectrometry-driven proteomics to interrogate molecular processes underlying the pathogenesis of lymphoid malignancies. He has authored or co-authored more than 164 peer-reviewed research publications and has contributed more than 40 chapters to professional textbooks in Pathology. Dr. Elenitoba-Johnson is currently serving as the Past-President of the Association for Molecular Pathology (2018-2019).

Secretary-Treasurer and Finance Committee Chair (2018-2019)

Daniel E. Sabath, MD, PhD
University of Washington Medical Center

Dr. Daniel Sabath is the head of the Hematology Division in the Department of Laboratory Medicine at the University of Washington. His main clinical responsibilities include directing the hematology laboratories at the University of Washington Medical Center and Harborview Medical Center, which includes basic hematology testing, coagulation and red cell disorders. Dr Sabath is also responsible for signing out hematopathology cases, both tissue- and bone marrow-based. Finally, Dr Sabath has significant signout responsibility for hematopathology molecular diagnostic cases, including B and T cell clonality, quantitative RT-PCR for BCR-ABL1, single gene mutation assays for *FLT3*, *CEPBA*, *JAK2*, *CALR*

and *NPM1* as well as a laboratory developed amplicon-based next-generation sequencing assay for mutations associated with myeloid stem cell neoplasms.

In addition to his clinical work, Dr Sabath has been collaborating with a local biotech startup company to develop a new assay for circulating tumor cells. This assay is currently in the final stages of clinical validation and will be used for patient testing beginning in July 2019. Dr. Sabath plans to offer this assay for clinical research purposes as well, and a number of investigators at the Seattle Cancer Care Alliance will incorporate this technology into their clinical research protocols.

Clinical Practice Committee Chair (2019-2020)

Dan Jones, MD, PhD

The Ohio State University

Dr. Dan Jones serves as Vice Chair and Professor of Pathology in The Ohio State University College of Medicine Department of Pathology. He also serves as Adjunct Professor in the Department of Biomedical Informatics and Director of Molecular Pathology for the James Cancer Hospital. Dr. Jones completed anatomic pathology residency training and hematopathology fellowship training at Brigham and Women's Hospital and did postdoctoral work at Harvard Medical School. He received his medical and doctoral degrees from Case Western Reserve University. He is currently Chair of the Clinical Practice Committee for the Association for Molecular Pathology and on the Molecular Diagnostics Expert Panel of the Clinical Laboratory Standards Institute (CLSI) and has served in various leadership roles within AMP, the Society for Hematopathology and other national pathology and laboratory organizations.

Dr. Jones has more than 20 years combined experience in academic medicine and industry, most recently serving as Medical Director of Cancer Diagnostics Services at Quest Diagnostics Nichols Institute. He was previously a Professor and oversaw clinical molecular diagnostics at The University of Texas MD Anderson Cancer Center. He has had a long-term funded research program in lymphocyte signaling and oncogenesis, with more than 250 scientific manuscripts and book chapters, emphasizing advanced diagnostics, targeted therapy monitoring and the molecular basis of leukemias and solid tumors.

Economic Affairs Committee Chair (2015-2019)

Samuel K. Caughron, MD

MAWD Pathology Group, PA

Dr. Samuel K. Caughron is the current Chair of AMP's Economic Affairs Committee, and a member of AMP's Professional Relations Committee and Board of Directors. Before becoming Chair, Dr. Caughron served on the Economic Affairs Committee as co-chair from 2010-2014, as well as serving on the Nominating Committee from 2012-2014.

In addition to his service to AMP, Dr. Caughron has served on professional pathology and medical committees for the College of American Pathologists, Association of Community Cancer Centers, Missouri Society of Pathology, the Catholic Medical Association Guild-Kansas City, American Pathology Foundation, the Kansas Medicare Carrier Advisory Committee, and the Medicare Evidence Development & Coverage Advisory Committee.

Dr. Caughron is the Chair of Pathology and Laboratory Medical Director for Shawnee Mission Medical Center. Since 2009, Dr. Caughron has also served as the President and CEO of the MAWD Pathology Group and the Founding Director of the MAWD Molecular Laboratory in Kansas City, Missouri. He is Board Certified in Anatomic and Clinical Pathology and Molecular Pathology. Dr. Caughron received his medical degree and did his Anatomic and Clinical Pathology residency at Creighton University Medical Center in Omaha, Nebraska. He completed his Molecular Genetic Pathology fellowship at Vanderbilt University. After his fellowship, he established and directed a molecular genetic pathology laboratory in Billings, Montana.

Membership Affairs Committee Chair (2019-2020)

Midhat S. Farooqi, MD, PhD
Children's Mercy Hospital

Dr. Midhat Farooqi is the Director of Molecular Oncology at Children's Mercy Hospital in Kansas City, Missouri and a member of the Department of Pathology & Laboratory Medicine and the Center for Pediatric Genomic Medicine there. He is an Assistant Professor of Pathology at the University of Missouri-Kansas City School of Medicine and a Clinical Assistant Professor of Pathology at the University of Kansas Medical Center. He received his undergraduate degree in Genetics from Texas A&M University, completed the MD/PhD program at the University of Texas Southwestern Medical Center in Dallas, and then finished a residency in clinical pathology at the same institution. He received subspecialty training in molecular genetic pathology from the University of Pennsylvania. He is currently involved the clinical interpretation and sign-out of laboratory genetic testing for both inherited and oncology cases, including constitutional whole exome sequencing and tumor somatic profiling. He has an interest in the development of new clinical diagnostic tests, especially for pediatric oncology. His research interests include epigenetic profiling and single cell sequencing of pediatric liquid and solid tumors.

Professional Relations Committee Chair (2018-2019)

Jordan Laser, MD
North Shore - Long Island Jewish Health System

Dr. Jordan Laser is a board certified anatomic, clinical and molecular genetic pathologist. Currently employed at Northwell Health System in New York, Dr. Jordan serves the Department of Pathology and Laboratory Medicine in the following roles: Medical Director, LIJ Pathology and Laboratory Medicine; Associate Medical Director, Core Laboratories, Senior Director, Division of Cytogenetics and Molecular Pathology; and Director, Division of Near Patient Testing. His expertise includes, molecular and genomic medicine, laboratory management, healthcare finance and standards and regulations.

Publication & Communication Committee Chair (2018-2019)

Paul G. Rothberg, PhD
University Rochester Medical Center

Dr. Paul Rothberg is a Professor of Pathology and Laboratory Medicine at the University of Rochester School of Medicine and Dentistry, and Director of the Molecular Diagnosis Laboratory. He is a board certified in Clinical Molecular Genetics by the American Board of Medical Genetics and Genomics, and

holds a certificate of qualification as a laboratory director in the areas of molecular genetics, molecular virology and molecular oncology testing from the New York State Department of Health. He earned a BA in Chemistry at Queens College, City University of New York, and a Ph.D. in Molecular Biology at Stony Brook University, and then did a postdoctoral fellowship at the Fox Chase Cancer Center. He has held positions as a cancer research scientist at the Roswell Park Cancer Institute, and director of the molecular genetics laboratory at Children's Mercy Hospital in Kansas City.

He is a member of the Association for Molecular Pathology and in that organization has served as Chair of the Genetics Subdivision, Genetics Representative to the Clinical Practice Committee and liaison from the Clinical Practice Committee to the Molecular Oncology Committee of the College of American Pathologists. Currently he is Chair of the AMP Publication and Communications Committee and member of Joint Journal Operating Committee for the Journal of Molecular Diagnostics. Dr. Rothberg is on the editorial boards for Genetic Testing and Molecular Biomarkers, and the Journal of Molecular Diagnostics.

Training & Education Committee Chair (2018-2019)

Cecilia Ching Sze Yeung, MD

Fred Hutchinson Cancer Research Center

Dr. Cecilia Yeung is an Associate Member at the Fred Hutchinson Cancer Research Center where she serves as the medical director of the Fred Hutch Clinical Trials Laboratories including Molecular Oncology, Integrated Clinical Trials Pathology and the Targeted Proteomics Laboratory. She is an Assistant Professor at the University of Washington, Department of Anatomic Pathology where she serves as the chair of the Clinical Competency Committee for the Molecular Genetics Pathology Fellowship and the director for the Molecular Pathology Elective. She is the co-coordinator and speaker of the Molecular Pathology Lecture Series for residents and fellows. She is a member of the Board of Directors and the chair of the Teaching and Education Committee at the Association for Molecular Pathology. Her clinical appointment at Seattle Cancer Care Alliance is where she focuses her pathology diagnostic skills in immunotherapy, transplant, and hematopathology. Her research interest focuses on developing novel molecular diagnostics for hematologic malignancies and improving clinical trials correlative data via implementation of better translational medicine diagnostic assays.

Dr. Yeung's professional titles include: Associate Member - Fred Hutchinson Cancer Research Center, Clinical Research Division; Associate Professor - University of Washington, Dept. of Pathology; Medical Director – Fred Hutch Clinical Trials Laboratories, Fred Hutchinson Cancer Research Center; Pathologist - Seattle Cancer Care Alliance

Genetics Subdivision Chair (2019-2020)

Thomas W. Prior, PhD

Case Western University

Dr. Thomas Prior is a Professor of Pathology and Director of the Molecular Genetics Laboratory at Case Western Reserve University. I joined The Case Western University faculty in March of 2018, after spending 28 years on the faculty at Ohio State University. I have a longstanding research interest in the genetics of neuromuscular disorders, specifically in clinical applications and mutation detection. I have

been most recently involved in the genetic disorder, spinal muscular atrophy (SMA). While at Ohio State, we developed the first SMA carrier test and I have been involved in both population carrier and newborn screening projects for SMA. I have also been active in determining the role of the SMN2 gene and other gene modifiers in effecting the disease phenotype and the identification of new types of mutations in the spinal muscular atrophy gene and their effect on the disease severity. The Laboratory has also been active in several SMA clinical trials.

I have always enjoyed and taken my role as an educator very seriously. I served on the Board of Directors of the American Board of Medical Genetics and Genomics from 2011 to 2016. My laboratory performs a major teaching function at Case Western. Pathology residents, medical students, genetic fellows, graduate students and genetic counseling students perform rotations through the laboratory every year. I have also been the advisor of 6 PhD graduate students and have served on many graduate student committees.

Hematopathology Subdivision Chair (2018-2019)

Annette Kim, MD, PhD

Brigham and Women's Hospital

Dr. Annette Kim is an Associate Professor of Pathology at Harvard Medical School and a practicing hematopathologist and molecular pathologist at Brigham and Women's Hospital. She has prior training in synthetic organic chemistry as well as structural biology and spent several years in the pharmaceutical industry prior to her return to academia. Since returning to clinical practice, she has practiced diagnostic hematopathology and molecular pathology, and is the Associate Director of the Center for Advanced Molecular Diagnostics in which role she has directed assay validation and quality assurance. Her research program has focused on the study of myeloid neoplasms, mutational patterns in hematopoietic neoplasms, and test utilization. Her research program has identified diagnostic and prognostic small non-coding RNAs in MDS via next generation sequencing and has defined the role of hypermethylation in the regulation of miRNAs in MDS. She has studied the effects of potential therapeutic compounds on cellular function in miRNA-based models of the MDS and in primary clinical samples using single cell phenotyping by mass cytometry with correlation to the mutational profiles of these samples. In addition, she has experience implementing, receiving funding for, and publishing on efforts in test utilization management, conducting studies on cost effective practice of hematopathology. She has been an active member of the Association of Molecular Pathology, serving as Chair of several committees and a member of the Executive Committee, Strategic Opportunities Committee, and Board. She also serves on the College of American Pathologists Molecular Oncology Committee. Through these Societies she has published key papers on myeloid mutational patterns and performance of FDA companion diagnostics and laboratory developed assays, including performance of next generation sequencing assays.

Infectious Diseases Subdivision Chair (2019-2020)

Frederick S. Nolte, PhD

Medical University of South Carolina

Dr. Frederick (Rick) Nolte is currently Professor and Vice Chair for Laboratory Medicine in the Department of Pathology and Laboratory Medicine, and Medical Director of Clinical Laboratories, and Molecular

Pathology at the Medical University of South Carolina. He is a Diplomate of the American Board of Medical Microbiology and a Fellow of the American Academy of Microbiology. Dr. Nolte completed his B.S. degree in biology at the University of Cincinnati and his Ph.D. in medical microbiology at the Ohio State University. Dr. Nolte completed a postdoctoral fellowship in public health and medical laboratory microbiology at the University of Rochester. Prior to coming to MUSC in 2007 he spent 18 years at Emory University School of Medicine where he was a Professor of Pathology and Laboratory Medicine and Director of the Clinical Microbiology, Molecular Diagnostic, and Serology Laboratories, Emory Medical Laboratories. He is active in and held positions of responsibility in the American Society for Microbiology, Association for Molecular Pathology, Clinical and Laboratory Standards Institute, Infectious Diseases Society of America, American Society for Clinical Pathology, American Association for Clinical Chemistry, and College of American Pathologists. He has authored numerous book chapters, practice guidelines, and more than 100 peer-reviewed publications in the areas of clinical microbiology and molecular diagnostics. He has served on the scientific advisory boards and provided consulting services to many start-up and established diagnostic companies. In addition he has experience with FDA clinical trial work and served as a member and consultant to the CDRH FDA Microbiology Devices Panel and has served on NIH and CDC advisory panels.

Solid Tumors Subdivision Chair (2018-2019)

Roger D. Klein, MD, JD

Dr. Roger D. Klein is current Chair of the AMP's Solid Tumor Subdivision, and a member AMP's Professional Relations Committee, Strategic Opportunities Committee, and Board of Directors. Dr. Klein served as Chair of Professional Relations Committee from 2011-2017, during which time AMP became the "go to organization" for information, public policy development, partnership, and advocacy for "all things molecular" in the diagnostic laboratory testing arena. Through these activities, and his membership on the AMP Economic Affairs Committee and other distinguished working groups and projects, Dr. Klein played a pivotal role in helping to shape and influence CPT coding, pricing, reimbursement, accreditation quality, regulatory, and intellectual property policies that profoundly impact our membership and our field. Finally, Dr. Klein was a key expert, advisor, and representative for AMP in *Association for Molecular Pathology v. Myriad Genetics*, AMP's landmark lawsuit in which the U.S. Supreme Court unanimously invalidated patents on human genes, a decision that proved central to the adoption of massively parallel sequencing in the clinic.

In addition to his service with AMP Dr. Klein has served on major molecular pathology, laboratory medicine, evidence, oncology, and CPT coding and reimbursement related committees for of College of American Pathologists (CAP), American Medical Association (AMA), with the American Society of Clinical Oncology (ASCO), and Agencies within the Department of Health and Human Services (HHS). Dr. Klein is current a private consultant, a Faculty Fellow at the Arizona State University Sandra Day O'Connor College of Law's Center for Law, Science & Innovation, and an Expert with the Federalist Society Regulatory Transparency Project's FDA & Health Working Group. He received his medical degree at Case Western Reserve University and completed post-graduate training at Yale School of Medicine and Mayo Clinic. He is also a graduate of Yale Law School.

International Affairs Committee Chair (2017-2019)

Rami Mahfouz, MD

American University of Beirut Medical Center

Dr. Rami Mahfouz earned his medical degree from the American University of Beirut followed by a Clinical Pathology residency and a Fellowship in Molecular Pathology at St Jude Children's Research Hospital in Memphis, Tennessee focusing on HLA and molecular diagnostics and microarrays technology in research. In 2002, he joined the Department of Pathology and Laboratory Medicine at the American University of Beirut Medical Center as Assistant Professor and worked since then on establishing a Molecular Diagnostics Laboratory with a service scope covering different specialties including Transplantation, Molecular Microbiology, and Molecular Pathology.

His research interests include Natural killer cell immunoglobulin-like receptors (KIR) genotyping, HLA associations, and molecular thrombophilia profiling. He has more than 160 publications some in high impact factor journals like NATURE COMMUNICATIONS, BLOOD and CANCER CELL and serves as Associate and Executive editor on several international journals including *GENE* and *META GENE*.

He is currently a Tenured Professor and Head of Division of Clinical Pathology in the Department of Pathology and Laboratory Medicine at AUBMC and the Director of the Histocompatibility and Molecular Diagnostics Laboratory, Director of the Residency Training Program, and Vice-Chairman of the Biomedical Institutional Review Board. He is a member of several international and professional societies including the College of American Pathologists (CAP), the American Society of Histocompatibility and Immunogenetics (ASHI), and the American Association of Molecular Pathologists (AMP)

The Following BOD Members are unable to attend the June 2019 Corporate Advisory Council Event

Program Committee Chair (2019)

Neal Lindeman, MD

Brigham & Women's Hospital

Informatics Subdivision Chair (2019-2020)

Somak Roy, MD

University of Pittsburgh Medical Center